Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1464-410X.2007.06844.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Retracted] Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
Int J Oncol
February 2025
Department of Experimental Medicine, Laboratory of Radiobiology, University of L'Aquila, I-67100 L'Aquila, Italy.
Following the publication of the above article, a concerned reader drew to the Editor's attention that certain of the western blot assay data shown in Fig. 4G on p. 717 were strikingly similar to data that had appeared in a paper published previously in the journal , which had been written by different authors at different research institutes.
View Article and Find Full Text PDFEscalating the dose of high-dose-rate brachytherapy combined with external beam radiotherapy improves the disease control rate in patients with high- or very-high-risk prostate cancer.
Brachytherapy
December 2024
Department of Radiology, Wakayama Medical University, Wakayamashi, Wakayama, Japan.
Purpose: High-dose-rate brachytherapy (HDR-BT) combined with external beam radiotherapy (EBRT) is an effective treatment for patients with high- and very-high-risk prostate cancer. We sought to identify the factors associated with reduced biochemical recurrence rates following HDR-BT.
Methods: A total of 304 patients with high- or very-high-risk prostate cancer who underwent HDR-BT and EBRT were analyzed.
Total penectomy as treatment option for solitary penile metastasis in hormone sensitive metastatic prostate cancer (mHSPC): Case report with surgical technique.
Urol Case Rep
January 2025
Department of Urology, Clinical Centre of Montenegro, Ljubljanska bb, 81000, Podgorica, Montenegro.
We present a case of a 66-year-old man with a three-year history of Gleason 10 prostate cancer (PCa), who presented with penile pain, erythema, and induration of the penile shaft. His cancer was treated with androgen deprivation therapy (ADT), radiotherapy, and apalutamide, resulting in PSA reduction; however, a solitary penile lesion persisted, necessitating radical penectomy. At 12 months post-surgery, PSA levels and magnetic resonance imaging findings remained stable, with no signs of metastasis.
View Article and Find Full Text PDFPatterns of recurrence following radiation and ADT for pathologic lymph node positive prostate cancer: A multi-institutional study.
Pract Radiat Oncol
December 2024
Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH.
Background And Objective: We evaluate prognostic factors and patterns of recurrence in patients who received RT ± androgen deprivation therapy (ADT) for pathologic node-positive (pN1) prostate cancer (PCa) in a multi-institutional cohort.
Methods: Data from patients with pN1 PCa and received RT with short term (ST, ≤6 mo) or long term (LT, >6 mo) ADT were obtained from 4 academic institutions. Biochemical progression free survival (bPFS) and distant metastasis free survival (DMFS) were evaluated.
Pelvis Or Involved Node Treatment: Eradicating Recurrence in Prostate Cancer (POINTER-PC) - study protocol paper for a phase III multicentre, open-label randomised controlled trial.
BMJ Open
December 2024
Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
Introduction: Prostate cancer (PCa) is the most common cancer in men. Recurrence may occur in up to half of patients initially treated with curative intent for high-risk localised/locally advanced PCa. Pelvic nodal recurrence is common in this setting, but no clear standard of care exists for these patients, with potential therapeutic approaches including stereotactic body radiotherapy (SBRT) to the involved node(s) alone, extended nodal irradiation (ENI) to treat sites of potential micrometastatic spread in addition to involved node(s) and androgen deprivation therapy with or without additional systemic anticancer therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!